Naji Gehchan - 22 Jan 2025 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
Chief Medical & Development Officer
Signature
By: /s/ Samantha Eldredge, as Attorney-in-Fact
Issuer symbol
KYTX
Transactions as of
22 Jan 2025
Net transactions value
$0
Form type
4
Filing time
24 Jan 2025, 20:05:04 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYTX Stock Option (right to buy) Award $0 +425,000 $0.000000 425,000 22 Jan 2025 Common Stock 425,000 $3.29 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4th of the shares subject to the option shall vest on January 22, 2026, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Remarks:

Chief Medical & Development Officer